Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maha Abdel-Kader

Psychiatry Manassas, VA Medical Doctor

NPI 1730172065 CMS profile 33792

8680 Hospital Way, Manassas, VA 20110

Open in the dashboard

General payments

$2,371

145 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maha Abdel-Kader of Manassas, VA is reported in the CMS Open Payments database as having received $2,371 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $359 19
2024 General $21 1
2023 General $100 4
2022 General $23 1
2021 General $16 1
2020 General $341 25
2019 General $1,510 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maha Abdel-Kader
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Maha Abdel-Kader were reported at $359. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Maha Abdel-Kader Psychiatry median Middle half National median
2019 $1,510 $184 $59–$605 $163
2020 $341 $119 $36–$372 $114
2021 $16 $143 $43–$576 $132
2022 $23 $153 $50–$590 $149
2023 $100 $170 $56–$651 $160
2024 $21 $179 $57–$673 $164
2025 $359 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $326 27 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $319 18 payments
  3. Supernus Pharmaceuticals, Inc. $287 16 payments
  4. Lundbeck LLC $227 13 payments
  5. Sunovion Pharmaceuticals Inc. $173 17 payments
  6. Neos Therapeutics, LP $148 8 payments
  7. Otsuka America Pharmaceutical, Inc. $146 12 payments
  8. Ironshore Pharmaceuticals Inc. $142 4 payments
  9. Janssen Pharmaceuticals, Inc $100 4 payments
  10. AbbVie, Inc. $89 4 payments
  11. Other $414 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,371 145 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $313 25 payments
  2. Qelbree $215 13 payments
  3. LATUDA $173 17 payments
  4. Trintellix $169 10 payments
  5. BRINTELLIX $149 9 payments
  6. Adzenys XR-ODT $148 8 payments
  7. COTEMPLA XR-ODT $148 8 payments
  8. Jornay PM 20mg capsules (Bottle of 100) $142 4 payments
  9. REXULTI $115 9 payments
  10. VRAYLAR Neuroscience $89 4 payments
  11. Other $833 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

488

Median for Psychiatry & Neurology: 100

Drug cost

$11,802

Median for Psychiatry & Neurology: $2,986

Branded share of claims

27%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lisdexamfetamine Dimesylate Generic 14 $5,416
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 42 $1,542
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 29 $1,336
Bupropion Xl Bupropion Hcl Brand 31 $762
Clonazepam Generic 47 $423
Trazodone Hcl Generic 45 $323
Duloxetine Hcl Generic 19 $316
Lamotrigine Generic 25 $297
Gabapentin Generic 20 $245
Fluoxetine Hcl Generic 30 $229

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record